BLTE - Company ID 0001889109
The table below shows BELITE BIO, INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M | -$4.44M |
| Capital expenditure | $71.00K | $116.00K | $63.00K | $394.00K | $74.00K | - |
| Investing cash flow | -$305.11M | -$110.57M | -$63.00K | -$394.00K | -$56.00K | -$20.00K |
| Dividends paid | - | - | - | - |
BELITE BIO, INC reported operating cash flow of -$36.99M for fiscal year 2025. That is down 26.5% from -$29.23M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$4.44M (FY 2020) to -$36.99M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $663.23M | $83.59M | $75.96M | $36.96M | -$583.00K | $28.06M |